Aldeyra Therapeutics, a clinical-stage biotech developing treatments for rare skin and eye diseases, raised the proposed deal size for its upcoming IPO on Friday. The Burlington, MA-based company now plans to raise $25 million by offering approximately 2.3 million shares (up from 2.0 million) at a price range of $10 to $12. At the midpoint of the revised range, it is expected to raise 14% greater proceeds than previously anticipated.
Aldeyra Therapeutics, which was founded in 2004, plans to list on the NASDAQ under the symbol ALDX. Aldeyra Therapeutics initially filed confidentially on December 4, 2013. Aegis Capital Corp. are the joint bookrunners on the deal. No pricing terms were disclosed.
